CHUGAI PHARMACEUTICAL CO., LTD.

Skip To Voice Support Menu
For Body
For Menu
For Local Menu

May 13

Determination of Terms and Conditions of Stock Options
(Stock Acquisition Rights)

May 07

Results of a Phase I/II Clinical Trial of a New Anti-Malignant Agent,
AF802, for ALK-Positive Non-Small Cell Lung Cancer
were Published Online on “The Lancet Oncology”

May 07

FDA Approves ACTEMRA^® for Children
Living with a Rare Form of Arthritis

Apr 25

Issuance of Stock Options (Stock Acquisition Rights)

Apr 19

Results of Phase II/III Clinical Trial of Ibandronate Sodium Hydrate
Injection, Bisphosphonate Antiresorptive Agent,
in Japanese Patients with Osteoporosis Presented

More

Apr 30: Updated Directors & Officers
Apr 25: Results for First Quarter of Fiscal Year 2013 (January - March, 2013)
Apr 25: 1Q Results (Jan 13 - Mar 13) Conference Call
Apr 18: Events & Presentations has been updated with the time of the Financial Results
Apr 01: Updated Directors & Officers

Chugai offers the latest corporate information via RSS web feeds.

Company profile and introduction of business activities of Chugai Pharmaceutical.

Chugai Pharmaceutical utilizes leading technologies in biopharmaceutical and molecular targeted drug discovery to create innovative drugs.

The Chugai Group takes proactive environmental measures in all of its business activities.

TSE Code:4519

Chart